期刊文献+

倍他乐克对心力衰竭并心房纤颤患者心功能和心室率的影响

Effect of Betaloc on Heart Function and Ventricular Rate in the Patients with Chronic Cardiac Failure and Atrial Fibrillation
下载PDF
导出
摘要 目的观察倍他乐克对心力衰竭合并心房纤颤患者心功能和心室率的影响。方法选择慢性心力衰竭合并心房纤颤患者62例,随机分成2组。在综合治疗1w后,治疗组32例加倍他乐克+地高辛治疗;对照组30例,加地高辛治疗。2w后观察心功能和心室率变化的情况。结果倍他乐克+地高辛治疗组改善心功能和控制心室率的疗效明显强于地高辛组(P<0.01)。结论倍他乐克+地高辛能够改善心力衰竭合并心房纤颤患者的心功能,有效地控制患者较快的心室率,并且安全性高,是治疗心力衰竭合并心房纤颤患者的有效途径。 Objective To observe the effect of betaloc on heart function and ventricular rate in the patients with chronic cardiac failure(HF) and atrial fibrillation(AF).Methods Sixty-two patients with HF and AF were randomly divided into treatment group (32 cases) and control group (30 cases).The effect on heart funtion and ventricular rate was observed separately after 14 days.Results The effect in treatment group was remarkably better than that in control group.There was significant difference between two groups.Conclusion Betaloc may improve the clinical heart function of the patients with HF and AF,it could also effectively control their ventricular rate,with hyper-safety,it is a good approach to the treatment of the patients with HF and AF.
作者 陈志华
出处 《医学文选》 2005年第3期319-320,共2页 Anthology of Medicine
关键词 倍他乐克 地高辛 心力衰竭 心房纤颤 Betaloc Heart failure Atrial fibrillation
  • 相关文献

参考文献3

二级参考文献47

  • 1[1]Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation:incidence,risk factors , and prognosis in the Mannitoba Follow-up study [J].Am J Med,1995 ,98 :466-484.
  • 2[2]van den Berg MP,Tuinenberg AE,Crijns HJGM ,et al. Heart failure and atrial fibrillation:current concepts and controversies[J]. Heart,l997,77:309-313.
  • 3[3]Dries DL, Exner DV, Gersh B J, et al. Atrial fibrillation is aasociated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the AOLVD trials. Studies of Left Ventricular Dysfunction[J]. J Am Coll Cardiol, 1998,32: 695 -703.
  • 4[4]The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Results of a randomized, placebo-controlled multicentre trial in 239 patients [ J ]. Eur Heart J,1997,18:649-654.
  • 5[5]Hou ZY, Chang MS, Chet CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone [ J ].Eur Heart J,1995,16:521-528.
  • 6[6]Goldenberg IF, Lewis WR, Dias VC, et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and modetate to severe congestive cardiac failure[J]. Am J Cardiol, 1994,74:884-889.
  • 7[7]Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation [J]. Circulation, 1996,94: 1613-1621.
  • 8[8]Varriale P,Sedighi A. Acute management of ateial fibrillation and atrial flutter in the critical care unit:should it be ibutilide[J] ? Clin Cardiol,2000,23:265-268
  • 9[9]van Gelder IC, Crijns HJGM, van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of. chronic atrial fibrillation and flutter [ J ]. Am J Cardiol, 1991,68:41-46.
  • 10[10]Camm AJ ,Obel OA. Epidemiology and mechanism of atrial fibrillation and atrial flutter[ J ]. Am J Cardiol, 1996,78( 8A ) :3-1 1.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部